Back to top
more

Phibro Animal Health (PAHC)

(Delayed Data from NSDQ)

$26.11 USD

26.11
356,504

-0.39 (-1.47%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $26.13 +0.02 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

3 Reasons Growth Investors Will Love Phibro (PAHC)

by Zacks Equity Research

Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Best Growth Stocks to Buy for July 23rd

by Zacks Equity Research

PAHC, AFYA and ROAD made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 23, 2025.

Zacks Equity Research

Best Value Stocks to Buy for July 23rd

by Zacks Equity Research

NX, OPBK and PAHC made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 23, 2025.

Zacks Equity Research

Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Santanu Roy headshot

Beat the Market the Zacks Way: Curtiss-Wright, Oracle, Starbucks in Focus

by Santanu Roy

CW surged 26% after a Zacks upgrade, while ORCL and SBUX powered portfolio gains in a volatile, inflation-watched market.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY rides strong global demand and CyberKnife momentum, but order declines and backlog pressure temper the outlook.

Zacks Equity Research

Should You Add Edwards Lifesciences Stock to Your Portfolio Now?

by Zacks Equity Research

EW gains traction with surgical tech and TAVR growth, but macro pressures and FX headwinds weigh on margins.

Zacks Equity Research

Elevance Health Q2 Earnings Miss Estimates on Rising Medical Costs

by Zacks Equity Research

ELV's Q2 EPS slides 12.6% y/y and misses estimates as rising Medicaid and ACA costs weigh on the results.

Zacks Equity Research

ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal

by Zacks Equity Research

Zimmer Biomet eyes long-term gains with the $177M Monogram buyout, aiming to expand its robotic knee surgery offerings by 2027.

Zacks Equity Research

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Best Growth Stocks to Buy for July 17th

by Zacks Equity Research

QFIN, AFYA and PAHC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 17, 2025.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Phibro (PAHC)

by Zacks Equity Research

Phibro (PAHC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now

by Zacks Equity Research

XRAY gains traction with digital implants, R&D strength, and Q1 margin growth despite softness in Europe.

Zacks Equity Research

PAHC or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Encompass Health Opens Rehabilitation Hospital in Florida

by Zacks Equity Research

EHC opens its 23rd Florida rehab hospital in Daytona Beach, boosting access to care and supporting its 2025 growth plan.

Zacks Equity Research

Should You Continue to Hold Veracyte Stock in Your Portfolio Now?

by Zacks Equity Research

VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.

Zacks Equity Research

BD Partners With Waters to Build High-Volume Diagnostics Leader

by Zacks Equity Research

BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.

Zacks Equity Research

Best Growth Stocks to Buy for July 15th

by Zacks Equity Research

QFIN, AFYA and PAHC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 15, 2025.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High With More Upside Potential

by Vasundhara Sawalka

Stocks like KD, FIX, PAHC and DB are seeing price strength and have a high chance of carrying the momentum forward.

Zacks Equity Research

Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms

by Zacks Equity Research

BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.

Zacks Equity Research

Here's Why Phibro Animal Health (PAHC) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Phibro Animal Health (PAHC) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Phibro Animal Health (PAHC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Should You Continue to Hold STERIS Stock in Your Portfolio Now?

by Zacks Equity Research

STE rides on strong Healthcare and AST growth, but macro pressures and customer consolidation cloud its outlook.

Zacks Equity Research

Best Growth Stocks to Buy for July 10th

by Zacks Equity Research

GOOS, PAHC and DELL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 10, 2025.